Recombinant Human AP3B2 protein, His-tagged
Cat.No. : | AP3B2-920H |
Product Overview : | Recombinant Human AP3B2 protein (Gly838-Gln1082), fused to His-tag at N-terminus, was expressed in E.coli. |
- Specification
- Gene Information
- Related Products
Description : | Adaptor protein complex 3 (AP-3 complex) is a heterotrimeric protein complex involved in the formation of clathrin-coated synaptic vesicles. The protein encoded by this gene represents the beta subunit of the neuron-specific AP-3 complex and was first identified as the target antigen in human paraneoplastic neurologic disorders. The encoded subunit binds clathrin and is phosphorylated by a casein kinase-like protein, which mediates synaptic vesicle coat assembly. Defects in this gene are a cause of early-onset epileptic encephalopathy. |
Source : | E.coli |
Species : | Human |
Tag : | His |
Form : | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
Molecular Mass : | 30 kDa |
Protein length : | 245 |
Endotoxin : | <1.0EU per 1µg (determined by the LAL method) |
Purity : | >95% |
Applications : | Positive Control; Immunogen; SDS-PAGE; WB. |
Storage : | Avoid repeated freeze/thaw cycles. Store at 2-8 centigrade for one month. Aliquot and store at -80 centigrade for 12 months. |
Reconstitution : | Reconstitute in PBS or others. |
Gene Name : | AP3B2 |
Official Symbol : | AP3B2 |
Synonyms : | NAPTB; EIEE48 |
Gene ID : | 8120 |
mRNA Refseq : | NM_001278512.2 |
Protein Refseq : | NP_001265441.1 |
MIM : | 602166 |
UniProt ID : | Q13367 |
Products Types
◆ Recombinant Protein | ||
AP3B2-604M | Recombinant Mouse AP3B2 Protein, His (Fc)-Avi-tagged | +Inquiry |
AP3B2-9720H | Recombinant Human AP3B2, GST-tagged | +Inquiry |
AP3B2-1744M | Recombinant Mouse AP3B2 Protein | +Inquiry |
◆ Lysates | ||
AP3B2-8809HCL | Recombinant Human AP3B2 293 Cell Lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (20)
Ask a questionThe duration of efficacy of AP3B2 varies by disease and treatment regimen and needs to be evaluated with ongoing treatment and follow-up.
The results of different clinical trials vary, and the specific results need to be judged according to the actual research results and reports.
There is no clear evidence that the AP3B2 interacts with other drugs, but it is best to consult a doctor when using it.
AP3B2 is being investigated for cancer treatment, but its therapeutic effect is currently in the further experimental stage, and more clinical trials are needed to verify its efficacy.
Recombinant AP3B2 is being investigated for the treatment of autoimmune diseases, but its efficacy needs to be validated in more clinical trials.
At present, there is no sufficient research to prove whether the AP3B2 is safe for use in children, and it is necessary to follow the recommendations of doctors.
In general, the storage method of AP3B2 can refer to its product manual, pay attention to avoid high temperature, direct sunlight and other conditions.
The duration of treatment of AP3B2 varies according to the type of disease and treatment plan, and the doctor needs to make judgment and advice according to the actual situation.
The AP3B2 is involved in the intracellular protein transport process, regulating the localization and distribution of intracellular substances by promoting the formation and fusion of vesicles.
There is no evidence that the AP3B2 interacts with food, but it is best to follow your doctor's dietary recommendations.
The cost of treatment for AP3B2 varies by region, hospital, and treatment regimen, so consult your doctor or organization for specific information.
AP3B2 is being studied for the treatment of some hematopoietic diseases, such as partial anemia, but more research is needed to confirm this.
Current studies have shown that the recombinant AP3B2 protein has shown good safety and tolerability in clinical trials with few side effects, but different individuals may have different reactions, and the details are based on the recommendations of clinicians.
The specific use mode should follow the guidance and prescription of the clinician, and make reasonable use according to the condition and dosage requirements.
There is currently no direct evidence that the recombinant AP3B2 protein can be used to treat the novel coronavirus, but virologists are constantly working to find a treatment and hope to find more.
Recombinant AP3B2 has shown potential in some clinical trials to treat related diseases, but whether it can be completely cured needs to be evaluated on the basis of actual conditions.
Recombinant protein AP3B2 has been shown to improve immune function, but the specific effect varies according to individual differences and specific disease conditions.
The research progress of AP3B2 is very promising, and many clinical trials have confirmed its potential in the treatment of different diseases, but further research and verification are still needed.
Recombinant AP3B2 is currently being investigated for the treatment of a variety of diseases, including neurodegenerative diseases, immune system disorders, and tumors.
Yes, the efficacy of recombinant AP3B2 may vary by individual and disease type.
Customer Reviews (3)
Write a reviewStability of AP3B2 is very good, and it can maintain stable performance even after multiple uses.
Their service attitude is very good, always patiently answer our questions.
Catalytic activity is very excellent, which can greatly improve the efficiency and rate of chemical reaction, and provide a new way for industrial production.
Ask a Question for All AP3B2 Products
Required fields are marked with *
My Review for All AP3B2 Products
Required fields are marked with *
Inquiry Basket